Tags |
|
|
Links |
|
|
Advice You - Should You Be More Explicit When Managing Change?
Yes!
If you want to prevent comments like: “what the heck is going on here?” you might consider to be m
If you want to prevent comments like: “what the heck is going on here?” you might consider to be m
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ore explicit when dealing with change. This is especially relevant if you are guiding a change program.
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
Think about a change project and there is no explicit message about a new direction or focus. Even if yo
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
u are not able to explain what will happen after the change, you should communicate what will change in
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
elation to the current situation.
It is impossible to predict future changes and often change initiativ
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
es will take an unprecedented turn. Yet for larger projects and change initiatives that are driven from
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
a central point require an explicit approach. Main keyword for this approach are large projects and cent
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
al program management.
Obviously there are other ways. Therefore,
No (is also possible).
Think about
Obviously there are other ways. Therefore,
No (is also possible).
Think about
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
how we learn a language and the main mechanism behind the language:
http://ezinearticles.com/?Grammar-
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
Teaching:-Implicit-or-Explicit?&id=89342
“Grammar teaching should be implicit,” is the conclusion of th
“Grammar teaching should be implicit,” is the conclusion of th
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
article. And one of the reasons mentioned is that learning would otherwise be more boring.
And that co
And that co
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
uld be a similar argument against explicit change programs. For small initiatives it is true; "don't tel
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
l us what to do, that is boring!" Let the best change initiatives compete against each other (in larger
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
organizations) and evaluate which one will work best. This freedom is possible in decentralized and auto
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
omous units with an own focus. But it could also become a problem. And the problem rises at economic dow
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
nturns. That is often when a central change approach will be designed. Explicit.
“What is going on here
“What is going on here
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
,” is often heard in situation of a crisis. “Don’t tell me what to do,” is uttered in cases of financial
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
freedom because of a positive economic climate. Both situations require a different change approach, one
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
more explicit (crisis) and the other implicit when there is financial space to try a different way – bu
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
t in those situations, we will manage the change tacitly, without being too explicit...
© 2007 Hans Boo
© 2007 Hans Boo
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/13907/adviceyou-Should-You-Be-More-Explicit-When-Managing-Change.html">Should You Be More Explicit When Managing Change?</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/13907/adviceyou-Should-You-Be-More-Explicit-When-Managing-Change.html]Should You Be More Explicit When Managing Change?[/url]
Related Articles:
Satellite Radio Could be Just the Thing for You
Medical Billing - Distributing Duties
Logo Design - Your First Step Towards Business Success
Bookmark it:
|